Moleculin Biotech Inc (MBRX): Next-Year EPS Estimate 42.62%
As of 2026-03-24, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 42.62%.
On 2026-03-20, analyst consensus for MBRX's next-year EPS growth shifted from 42.55% to 42.62% — a positive change of 0.07 percentage points. The revised estimate has been sustained across 3 subsequent trading sessions.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 42.62%
- EPS growth this year
- N/A
- EPS next quarter (est)
- N/A
- Last price
- $2.25
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-03-24 | 42.62% | N/A | N/A | $2.25 |
| 2026-03-23 | 42.62% | N/A | N/A | $2.10 |
| 2026-03-20 | 42.62% | N/A | N/A | $2.06 |
| 2026-03-19 | 42.55% | N/A | N/A | $2.06 |
| 2026-03-18 | 81.69% | N/A | N/A | $2.08 |
| 2026-03-17 | 81.69% | N/A | N/A | $2.16 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Moleculin Biotech Inc's next-year EPS growth estimate?▾
As of 2026-03-24, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 42.62%, based on analyst consensus.
When was the latest EPS estimate revision for MBRX?▾
The most recent revision occurred on 2026-03-20, when analysts adjusted the next-year EPS growth estimate from 42.55% to 42.62%.
What sector and industry does Moleculin Biotech Inc belong to?▾
Moleculin Biotech Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MBRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moleculin Biotech Inc (MBRX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports